We have located links that may give you full text access.
Functional autoantibodies against Endothelin-1 receptor type A and Angiotensin II receptor type 1 in patients with preeclampsia.
Pregnancy Hypertension 2018 October
OBJECTIVES: Functional autoantibodies against Angiotensin II Receptor type 1 (AT1-AA) and Endothelin-1 Receptor type A (ETA-AA), which belong to the class of functional autoantibodies, have been discovered in patients with preeclampsia and in rodent models of pregnancy-induced hypertension. The aim of the study was to investigate the expression of these autoantibodies in relation to disease progression.
STUDY DESIGN: We included 10 controls and 41 cases defined as patients with gestational-induced hypertension, preeclampsia or HELLP syndrome.
MAIN OUTCOME: Serum obtained in the first trimester as well as at the time of disease development were analyzed by means of a biological assay of beating cardiomyocytes. We also measured the protein expression of IL-17A in these samples.
RESULTS: 100% of samples from patients with gestational induced hypertension, preeclampsia or HELLP syndrome expressed AT1-AA when they presented with clinical symptoms but not in samples from the first trimester. 44% of samples from patients with severe preeclampsia or HELLP syndrome expressed ETA-AA but only when they presented with clinical symptoms. The controls expressed neither AT1-AA nor ETA-AA. Approximately 40% of patients with severe preeclampsia or HELLP syndrome expressed IL-17A, both at the time of the onset of symptoms and in the first trimester.
CONCLUSION: Autoantibodies against the Angiotensin II receptor 1 and Endothelin receptor are developed in relation to pregnancy-induced hypertension and not present at the start of the pregnancy in these patients. IL-17A is increased in some patients with severe preeclampsia, but the expression is not related to the development of clinical symptoms.
STUDY DESIGN: We included 10 controls and 41 cases defined as patients with gestational-induced hypertension, preeclampsia or HELLP syndrome.
MAIN OUTCOME: Serum obtained in the first trimester as well as at the time of disease development were analyzed by means of a biological assay of beating cardiomyocytes. We also measured the protein expression of IL-17A in these samples.
RESULTS: 100% of samples from patients with gestational induced hypertension, preeclampsia or HELLP syndrome expressed AT1-AA when they presented with clinical symptoms but not in samples from the first trimester. 44% of samples from patients with severe preeclampsia or HELLP syndrome expressed ETA-AA but only when they presented with clinical symptoms. The controls expressed neither AT1-AA nor ETA-AA. Approximately 40% of patients with severe preeclampsia or HELLP syndrome expressed IL-17A, both at the time of the onset of symptoms and in the first trimester.
CONCLUSION: Autoantibodies against the Angiotensin II receptor 1 and Endothelin receptor are developed in relation to pregnancy-induced hypertension and not present at the start of the pregnancy in these patients. IL-17A is increased in some patients with severe preeclampsia, but the expression is not related to the development of clinical symptoms.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app